Pharma group asks USTR to drop India from watch list

The lobby group for India’s pharma industry has asked the US Trade Representative (USTR) office to remove India from its Priority Watch List of places that have weak enforcement of intellectual property laws.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Novo Nordisk secures China win ahead of key patent expiration

6 January 2026 Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.

Asia

Novo Nordisk ramps up semaglutide defence as generics lurk

9 December 2025 The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.

Asia

Novo Nordisk India strategy suffers semaglutide patent setback

4 December 2025 The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.

More features

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

Carpmaels & Ransford builds Munich UPC team with elite hire

Why the US is poised for a patent litigation surge in 2026

From migraine drugs to COVID vaccine spats, US lawsuits pile up

Deadline extended: Who are the world’s best in-house counsel?

‘All voices must be heard’: New CIPA president sets out plans for 2026

Insulin pump rivals face off in major trade secrets dispute hearing

Bayer enters COVID-19 vaccine row with three suits against major drugmakers

Pharma group asks USTR to drop India from watch list

More on this story

Editor's picks

Editor's picks

More features